GlassScriptPhysician profile
Vaibhav V Shah
NPI 1154508083
$18,762.52
in general payments reported to CMS, 2019-2025
10 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.06 · 2023: $29.87 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $15K · Consulting Fee: $3,095 · Food and Beverage: $634 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $14,930.15 |
| Consulting Fee | $3,095.00 |
| Food and Beverage | $634.31 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18,403.89 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $148.31 | 2025 | Dysport |
| Merz Pharmaceuticals, LLC | $85.00 | 2025 | Xeomin |
| Abbott Laboratories | $59.77 | 2022-2025 | Cardiomems |
| Genentech, INC. | $35.68 | 2025 | Ocrevus |
| Genentech USA, INC. | $29.87 | 2023 | Ocrevus |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vaibhav Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.